CRVO

CervoMed

• TipRanks·1d ago

  CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia

• Reuters·1d ago

  CervoMed says new Phase 2b MRI analysis supports neflamapimod slowing DLB progression

• Benzinga·1d ago

  CervoMed To Present Key Aspects Of Neflamapimod Clinical Program At 2026 Lewy Body Dementia Association Annual Meeting, Including Updates On Clinical Findings, Global Regulatory Alignment, And Finalized Phase 3 Trial Design In DLB

• Reuters·1d ago

  CERVOMED TO PROVIDE NEFLAMAPIMOD CLINICAL PROGRAM UPDATE AND PARTICIPATE IN A PANEL ON BIOMARKERS AT 2026 LEWY BODY DEMENTIA ASSOCIATION ANNUAL MEETING

• TipRanks·2d ago

  CervoMed (CRVO) Gets a Buy from JonesTrading

• TipRanks·03/23 20:38

  CervoMed Posts Investor Presentation Under Regulation FD Disclosure

• Reuters·03/23 20:08

  Cervomed Inc. Publishes Presentation Factsheet

• TipRanks·03/19 20:59

  CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results

• Dow Jones·03/19 18:42

  CervoMed Price Target Maintained With a $31.00/Share by D. Boral Capital

• Dow Jones·03/19 18:42

  CervoMed Is Maintained at Buy by D. Boral Capital

• Reuters·03/19 12:45

  BUZZ-CervoMed rises as experimental drug shows benefit in early-stage dementia patients

• TipRanks·03/19 11:56

  CervoMed’s neflamapimod shows efficacy in dementia with DLB

• Benzinga·03/19 11:42

  Investigators To Present New Analyses From Phase 2b RewinD-LB Clinical Study Of Neflamapimod Being Developed By Cervomed

• Reuters·03/19 11:31

  CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL

• Reuters·03/19 11:30

  CERVOMED ANNOUNCES NEW DATA AT THE AD/PD™ 2026 SCIENTIFIC CONFERENCE THAT REINFORCE NEFLAMAPIMOD’S POSITIVE EFFECTS IN DEMENTIA WITH LEWY BODIES (DLB) IN PATIENTS WITHOUT ALZHEIMER’S DISEASE CO-PATHOLOGY